{"protocolSection": {"identificationModule": {"nctId": "NCT01522417", "orgStudyIdInfo": {"id": "Medicure 11002"}, "organization": {"fullName": "Medicure", "class": "INDUSTRY"}, "briefTitle": "Shortened Aggrastat\u00ae Versus Integrilin in Percutaneous Coronary Intervention", "officialTitle": "A Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy of Tirofiban Using a High-Dose Bolus Plus a Shortened Infusion Duration Versus Label-Dosing Eptifibatide in Patients Undergoing Percutaneous Coronary Intervention", "acronym": "SAVI-PCI"}, "statusModule": {"statusVerifiedDate": "2021-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-04"}, "primaryCompletionDateStruct": {"date": "2018-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-01-27", "studyFirstSubmitQcDate": "2012-01-30", "studyFirstPostDateStruct": {"date": "2012-01-31", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2021-03-25", "resultsFirstSubmitQcDate": "2021-03-25", "resultsFirstPostDateStruct": {"date": "2021-04-20", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-04-20", "lastUpdatePostDateStruct": {"date": "2021-05-13", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Medicure", "class": "INDUSTRY"}, "collaborators": [{"name": "SCRI Development Innovations, LLC", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose this study is to assess whether a tirofiban regimen of a high-dose bolus plus a shortened infusion duration compared to label-dosing eptifibatide in patients undergoing percutaneous coronary intervention (PCI) is associated with a non-inferior composite rate of death, PCI-related myocardial infarction, urgent target vessel revascularization or in-hospital major bleeding within 48 hours following PCI or hospital discharge, whichever comes first."}, "conditionsModule": {"conditions": ["Myocardial Infarction", "Acute Coronary Syndromes", "Unstable Angina"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 535, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Short Tirofiban (Aggrastat)", "type": "EXPERIMENTAL", "description": "Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.\n\nPatients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).", "interventionNames": ["Drug: Short Tirofiban"]}, {"label": "Eptifibatide (Integrilin)", "type": "ACTIVE_COMPARATOR", "description": "Eptifibatide (Integrilin) will be dosed as a 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.\n\nPatients will receive eptifibatide (Integrilin) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).", "interventionNames": ["Drug: Eptifibatide"]}, {"label": "Long Tirofiban (Aggrastat)", "type": "EXPERIMENTAL", "description": "Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post PCI.\n\nPatients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).", "interventionNames": ["Drug: Long Tirofiban"]}], "interventions": [{"type": "DRUG", "name": "Short Tirofiban", "description": "25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.", "armGroupLabels": ["Short Tirofiban (Aggrastat)"], "otherNames": ["Aggrastat"]}, {"type": "DRUG", "name": "Eptifibatide", "description": "180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.", "armGroupLabels": ["Eptifibatide (Integrilin)"], "otherNames": ["Integrilin"]}, {"type": "DRUG", "name": "Long Tirofiban", "description": "25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post-PCI.", "armGroupLabels": ["Long Tirofiban (Aggrastat)"], "otherNames": ["Aggrastat"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The Composite Endpoint of Death, Periprocedural Myonecrosis (PPM), Urgent Target Vessel Revascularization (uTVR) or Major Bleeding", "description": "The composite of death (any-cause), periprocedural myonecrosis (defined as \u2265 3 times the upper limit of normal troponin and at least 20% or greater than the baseline troponin value), urgent target revascularization (repeat PCI or any CABG procedure after the index PCI on a non-selective basis in the target vessel because of recurrent myocardial ischemia) or non-CABG related major bleeding as quantified according to REPLACE-2 bleeding criteria.", "timeFrame": "48 hours or hospital discharge, whichever came first"}], "secondaryOutcomes": [{"measure": "The Composite Endpoint of Death, Periprocedural Myonecrosis or Urgent Target Vessel Revascularization", "description": "The composite of death (any-cause), periprocedural myonecrosis (defined as \u2265 3 times the upper limit of normal troponin and at least 20% or greater than the baseline troponin value), or urgent target revascularization (repeat PCI or any CABG procedure after the index PCI on a non-selective basis in the target vessel because of recurrent myocardial ischemia)", "timeFrame": "48 hours or hospital discharge, whichever came first"}, {"measure": "Individual Components of Death, Urgent Target Revascularization or Major Bleeding", "description": "Individual components of death (any-cause), urgent target revascularization (repeat PCI or any CABG procedure after the index PCI on a non-selective basis in the target vessel because of recurrent myocardial ischemia) or non-CABG related major bleeding as quantified according to REPLACE-2 major bleeding criteria.", "timeFrame": "48 hours or hospital discharge, whichever came first"}, {"measure": "Individual Components of Periprocedural Myonecrosis", "description": "Individual components of periprocedural myonecrosis (PPM) (defined as \u2265 3 times, \u2265 10 times, \u2265 20 times or \u2265 50 times the upper limit of normal troponin and at least 20% or greater than the baseline troponin value)", "timeFrame": "48 hours or hospital discharge, whichever came first"}, {"measure": "The Composite Endpoint of Death, Periprocedural Myonecrosis (PPM) (\u2265 10x Troponin), Urgent Target Vessel Revascularization (uTVR) or Major Bleeding", "description": "The composite of death (any-cause), periprocedural myonecrosis (defined as \u2265 10 times the upper limit of normal troponin and at least 20% or greater than the baseline troponin value), urgent target revascularization (repeat PCI or any CABG procedure after the index PCI on a non-selective basis in the target vessel because of recurrent myocardial ischemia) or non-CABG related major bleeding as quantified according to REPLACE-2 bleeding criteria.", "timeFrame": "48 hours or hospital discharge, whichever came first"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u226518 years of age\n* Scheduled to undergo PCI with an FDA, approved or cleared device (stent or procedures such as balloon angioplasty, rotoblation, AngioSculpt, laser atherectomy,etc.) in one or more native coronary target lesions\n* Written informed consent\n\nExclusion Criteria:\n\n* Primary PCI for STEMI as index procedure\n* Prior STEMI within 48 hours before randomization\n* Prior PCI within 30 days before randomization\n* Planned staged PCI within the subsequent 24 hours after index PCI\n* Use of abciximab within 7 days before randomization\n* Use of tirofiban or eptifibatide within 12 hours before randomization\n* Use of low-molecular weight heparin within 12 hours before randomization\n* Use of bivalirudin within 12 hours before randomization", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Steven V Manoukian, MD", "affiliation": "SCRI Development Innovations, LLC", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Osceola Regional Medical Center", "city": "Kissimmee", "state": "Florida", "zip": "34741", "country": "United States", "geoPoint": {"lat": 28.30468, "lon": -81.41667}}, {"facility": "Northside Hospital", "city": "Saint Petersburg", "state": "Florida", "zip": "33709", "country": "United States", "geoPoint": {"lat": 27.77086, "lon": -82.67927}}, {"facility": "Emory University Hospital Midtown", "city": "Atlanta", "state": "Georgia", "zip": "30308", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Emory University Hospital", "city": "Atlanta", "state": "Georgia", "zip": "30322", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "North Georgia Heart Center", "city": "Gainesville", "state": "Georgia", "zip": "30501", "country": "United States", "geoPoint": {"lat": 34.29788, "lon": -83.82407}}, {"facility": "Redmond Regional Medical Center", "city": "Rome", "state": "Georgia", "zip": "30165", "country": "United States", "geoPoint": {"lat": 34.25704, "lon": -85.16467}}, {"facility": "Archbold Medical Center", "city": "Thomasville", "state": "Georgia", "zip": "31792", "country": "United States", "geoPoint": {"lat": 30.83658, "lon": -83.97878}}, {"facility": "Lenox Hill Hospital", "city": "New York", "state": "New York", "zip": "10075", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "University of Oklahoma Health Sciences Center", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73104", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Doylestown Hospital", "city": "Doylestown", "state": "Pennsylvania", "zip": "18901", "country": "United States", "geoPoint": {"lat": 40.31011, "lon": -75.12989}}, {"facility": "Penn Presbyterian Medical Center", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19104", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Centennial Heart", "city": "Nashville", "state": "Tennessee", "zip": "37203", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}, {"facility": "Chippenham Hospital", "city": "Richmond", "state": "Virginia", "zip": "23225", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Decision to proceed to PCI, access site for PCI (transradial or transfemoral) and intended oral P2Y12 antagonist agent used post-randomization were all pre-specified prior to randomization to treatment groups.", "recruitmentDetails": "Date first patient enrolled: 12 June 2012 ; Last patient completed 8 August 2018\n\nThe study enrolled both stable and UA/NSTEMI patients scheduled to undergo PCI in one or more native coronary target lesions.", "groups": [{"id": "FG000", "title": "Short Tirofiban (Aggrastat)", "description": "Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.\n\nPatients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).\n\nShort Tirofiban: 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI."}, {"id": "FG001", "title": "Eptifibatide (Integrilin)", "description": "Eptifibatide (Integrilin) will be dosed as a 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.\n\nPatients will receive eptifibatide (Integrilin) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).\n\nEptifibatide: 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first."}, {"id": "FG002", "title": "Long Tirofiban (Aggrastat)", "description": "Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post PCI.\n\nPatients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).\n\nLong Tirofiban: 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post-PCI."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "209"}, {"groupId": "FG001", "numSubjects": "202"}, {"groupId": "FG002", "comment": "Randomization into the long tirofiban arm was initiated on 14 June 2013.", "numSubjects": "124"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "209"}, {"groupId": "FG001", "numSubjects": "202"}, {"groupId": "FG002", "comment": "Randomization into the long tirofiban arm was completed on 1 February 2018.", "numSubjects": "124"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Modified intention-to-treat (mITT) - all randomized patients who underwent PCI and received study drug", "groups": [{"id": "BG000", "title": "Short Tirofiban (Aggrastat)", "description": "Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.\n\nPatients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).\n\nShort Tirofiban: 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI."}, {"id": "BG001", "title": "Eptifibatide (Integrilin)", "description": "Eptifibatide (Integrilin) will be dosed as a 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.\n\nPatients will receive eptifibatide (Integrilin) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).\n\nEptifibatide: 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first."}, {"id": "BG002", "title": "Long Tirofiban (Aggrastat)", "description": "Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post PCI.\n\nPatients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).\n\nLong Tirofiban: 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post-PCI."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "209"}, {"groupId": "BG001", "value": "202"}, {"groupId": "BG002", "value": "124"}, {"groupId": "BG003", "value": "535"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "63.7", "spread": "9.7"}, {"groupId": "BG001", "value": "63.7", "spread": "10.1"}, {"groupId": "BG002", "value": "62.6", "spread": "10.9"}, {"groupId": "BG003", "value": "63.3", "spread": "10.2"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "57"}, {"groupId": "BG001", "value": "61"}, {"groupId": "BG002", "value": "40"}, {"groupId": "BG003", "value": "158"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "152"}, {"groupId": "BG001", "value": "141"}, {"groupId": "BG002", "value": "84"}, {"groupId": "BG003", "value": "377"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "17"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "202"}, {"groupId": "BG001", "value": "195"}, {"groupId": "BG002", "value": "121"}, {"groupId": "BG003", "value": "518"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "1"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "6"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "18"}, {"groupId": "BG003", "value": "65"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "175"}, {"groupId": "BG001", "value": "173"}, {"groupId": "BG002", "value": "103"}, {"groupId": "BG003", "value": "451"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "11"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "209"}, {"groupId": "BG001", "value": "202"}, {"groupId": "BG002", "value": "124"}, {"groupId": "BG003", "value": "535"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "The Composite Endpoint of Death, Periprocedural Myonecrosis (PPM), Urgent Target Vessel Revascularization (uTVR) or Major Bleeding", "description": "The composite of death (any-cause), periprocedural myonecrosis (defined as \u2265 3 times the upper limit of normal troponin and at least 20% or greater than the baseline troponin value), urgent target revascularization (repeat PCI or any CABG procedure after the index PCI on a non-selective basis in the target vessel because of recurrent myocardial ischemia) or non-CABG related major bleeding as quantified according to REPLACE-2 bleeding criteria.", "populationDescription": "As per the protocol, a patient must have a pre-PCI troponin measurement and at least one troponin measurement within 48 hours following PCI or hospital discharge, whichever comes first, otherwise they were excluded from the primary composite endpoint.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "48 hours or hospital discharge, whichever came first", "groups": [{"id": "OG000", "title": "Short Tirofiban (Aggrastat)", "description": "Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.\n\nPatients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).\n\nShort Tirofiban: 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI."}, {"id": "OG001", "title": "Eptifibatide (Integrilin)", "description": "Eptifibatide (Integrilin) will be dosed as a 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.\n\nPatients will receive eptifibatide (Integrilin) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).\n\nEptifibatide: 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first."}, {"id": "OG002", "title": "Long Tirofiban (Aggrastat)", "description": "Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post PCI.\n\nPatients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).\n\nLong Tirofiban: 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post-PCI."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "202"}, {"groupId": "OG001", "value": "194"}, {"groupId": "OG002", "value": "123"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "48"}]}]}]}, {"type": "SECONDARY", "title": "The Composite Endpoint of Death, Periprocedural Myonecrosis or Urgent Target Vessel Revascularization", "description": "The composite of death (any-cause), periprocedural myonecrosis (defined as \u2265 3 times the upper limit of normal troponin and at least 20% or greater than the baseline troponin value), or urgent target revascularization (repeat PCI or any CABG procedure after the index PCI on a non-selective basis in the target vessel because of recurrent myocardial ischemia)", "populationDescription": "As per the protocol, a patient must have a pre-PCI troponin measurement and at least one troponin measurement within 48 hours following PCI or hospital discharge, whichever comes first, otherwise they were excluded from the primary composite endpoint.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "48 hours or hospital discharge, whichever came first", "groups": [{"id": "OG000", "title": "Short Tirofiban (Aggrastat)", "description": "Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.\n\nPatients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).\n\nShort Tirofiban: 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI."}, {"id": "OG001", "title": "Eptifibatide (Integrilin)", "description": "Eptifibatide (Integrilin) will be dosed as a 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.\n\nPatients will receive eptifibatide (Integrilin) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).\n\nEptifibatide: 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first."}, {"id": "OG002", "title": "Long Tirofiban (Aggrastat)", "description": "Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post PCI.\n\nPatients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).\n\nLong Tirofiban: 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post-PCI."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "202"}, {"groupId": "OG001", "value": "194"}, {"groupId": "OG002", "value": "123"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "45"}]}]}]}, {"type": "SECONDARY", "title": "Individual Components of Death, Urgent Target Revascularization or Major Bleeding", "description": "Individual components of death (any-cause), urgent target revascularization (repeat PCI or any CABG procedure after the index PCI on a non-selective basis in the target vessel because of recurrent myocardial ischemia) or non-CABG related major bleeding as quantified according to REPLACE-2 major bleeding criteria.", "populationDescription": "mITT", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "48 hours or hospital discharge, whichever came first", "groups": [{"id": "OG000", "title": "Short Tirofiban (Aggrastat)", "description": "Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.\n\nPatients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).\n\nShort Tirofiban: 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI."}, {"id": "OG001", "title": "Eptifibatide (Integrilin)", "description": "Eptifibatide (Integrilin) will be dosed as a 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.\n\nPatients will receive eptifibatide (Integrilin) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).\n\nEptifibatide: 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first."}, {"id": "OG002", "title": "Long Tirofiban (Aggrastat)", "description": "Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post PCI.\n\nPatients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).\n\nLong Tirofiban: 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post-PCI."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "202"}, {"groupId": "OG002", "value": "124"}]}], "classes": [{"title": "Death", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "uTVR", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "REPLACE-2 Major Bleeding", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "4"}]}]}]}, {"type": "SECONDARY", "title": "Individual Components of Periprocedural Myonecrosis", "description": "Individual components of periprocedural myonecrosis (PPM) (defined as \u2265 3 times, \u2265 10 times, \u2265 20 times or \u2265 50 times the upper limit of normal troponin and at least 20% or greater than the baseline troponin value)", "populationDescription": "As per the protocol, a patient must have a pre-PCI troponin measurement and at least one troponin measurement within 48 hours following PCI or hospital discharge, whichever comes first, otherwise they were excluded from the individual PPM endpoints.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "48 hours or hospital discharge, whichever came first", "groups": [{"id": "OG000", "title": "Short Tirofiban (Aggrastat)", "description": "Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.\n\nPatients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).\n\nShort Tirofiban: 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI."}, {"id": "OG001", "title": "Eptifibatide (Integrilin)", "description": "Eptifibatide (Integrilin) will be dosed as a 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.\n\nPatients will receive eptifibatide (Integrilin) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).\n\nEptifibatide: 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first."}, {"id": "OG002", "title": "Long Tirofiban (Aggrastat)", "description": "Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post PCI.\n\nPatients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).\n\nLong Tirofiban: 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post-PCI."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "202"}, {"groupId": "OG001", "value": "194"}, {"groupId": "OG002", "value": "123"}]}], "classes": [{"title": "\u2265 3 times ULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "45"}]}]}, {"title": "\u2265 10 times ULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "28"}]}]}, {"title": "\u2265 20 times ULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "27"}, {"groupId": "OG002", "value": "21"}]}]}, {"title": "\u2265 50 times ULN", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "19"}, {"groupId": "OG002", "value": "9"}]}]}]}, {"type": "SECONDARY", "title": "The Composite Endpoint of Death, Periprocedural Myonecrosis (PPM) (\u2265 10x Troponin), Urgent Target Vessel Revascularization (uTVR) or Major Bleeding", "description": "The composite of death (any-cause), periprocedural myonecrosis (defined as \u2265 10 times the upper limit of normal troponin and at least 20% or greater than the baseline troponin value), urgent target revascularization (repeat PCI or any CABG procedure after the index PCI on a non-selective basis in the target vessel because of recurrent myocardial ischemia) or non-CABG related major bleeding as quantified according to REPLACE-2 bleeding criteria.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "48 hours or hospital discharge, whichever came first", "groups": [{"id": "OG000", "title": "Short Tirofiban (Aggrastat)", "description": "Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.\n\nPatients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).\n\nShort Tirofiban: 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI."}, {"id": "OG001", "title": "Eptifibatide (Integrilin)", "description": "Eptifibatide (Integrilin) will be dosed as a 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.\n\nPatients will receive eptifibatide (Integrilin) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).\n\nEptifibatide: 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first."}, {"id": "OG002", "title": "Long Tirofiban (Aggrastat)", "description": "Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post PCI.\n\nPatients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).\n\nLong Tirofiban: 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post-PCI."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "202"}, {"groupId": "OG001", "value": "194"}, {"groupId": "OG002", "value": "123"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "32"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "48 hours or hospital discharge, whichever came first", "description": "The Investigator periodically assessed patients for the occurrence of adverse events. To avoid bias in eliciting adverse events, patients were asked the following non-leading question: \"How are you feeling?\" All adverse events (serious and non-serious) reported by the patient will be followed until the event has resolved or has stabilized.", "eventGroups": [{"id": "EG000", "title": "Short Tirofiban (Aggrastat)", "description": "Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.\n\nPatients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).\n\nShort Tirofiban: 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.", "deathsNumAffected": 0, "deathsNumAtRisk": 209, "seriousNumAffected": 8, "seriousNumAtRisk": 209, "otherNumAffected": 45, "otherNumAtRisk": 209}, {"id": "EG001", "title": "Eptifibatide (Integrilin)", "description": "Eptifibatide (Integrilin) will be dosed as a 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.\n\nPatients will receive eptifibatide (Integrilin) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).\n\nEptifibatide: 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.", "deathsNumAffected": 1, "deathsNumAtRisk": 202, "seriousNumAffected": 11, "seriousNumAtRisk": 202, "otherNumAffected": 55, "otherNumAtRisk": 202}, {"id": "EG002", "title": "Long Tirofiban (Aggrastat)", "description": "Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post PCI.\n\nPatients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).\n\nLong Tirofiban: 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post-PCI.", "deathsNumAffected": 0, "deathsNumAtRisk": 124, "seriousNumAffected": 7, "seriousNumAtRisk": 124, "otherNumAffected": 50, "otherNumAtRisk": 124}], "seriousEvents": [{"term": "Angina Pectoris", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Coronary Artery Dissection", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Cardiac Arrest", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Cardiac Tamponade", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Myocardial Infarction", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Post-Procedural Myocardial Infarction", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Overdose", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Vascular pseudoaneurysm", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 124}]}, {"term": "Haemorrhage", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Hypertensive Crisis", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Vessel Perforation", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Gastrointestinal Angiodysplasia", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Gastrointestinal Haemorrhage", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Gastrointestinal Inflammation", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Dyspnea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Pulmonary Oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Respiratory Failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Vision Blurred", "organSystem": "Eye disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Contrast Media Allergy", "organSystem": "Immune system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Thrombosis in Device", "organSystem": "Product Issues", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Acute Kidney Injury", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Testicular Haemorrhage", "organSystem": "Reproductive system and breast disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}], "otherEvents": [{"term": "Catheter Site Haematoma", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 8, "numAffected": 8, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 124}]}, {"term": "Application Site Haemorrhage", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 124}]}, {"term": "Infusion Site Haematoma", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Non-Cardiac Chest Pain", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Pain", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Pyrexia", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Vessel Puncture Site Haematoma", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Vessel Puncture Site Haemorrhage", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Troponin Increased", "organSystem": "Investigations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 124}]}, {"term": "Haematocrit Decreased", "organSystem": "Investigations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Troponin T Increased", "organSystem": "Investigations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Blood Creatinine Increased", "organSystem": "Investigations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Blood Glucose Decreased", "organSystem": "Investigations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Occult Blood Positive", "organSystem": "Investigations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Troponin I Increased", "organSystem": "Investigations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Angina Pectoris", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Coronary Artery Dissection", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Bradycardia", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Myocardial Infarction", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Atrial Fibrillation", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Cardiac Arrest", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Cardiac Failure Congestive", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Cardiac Tamponade", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Intracardiac Thrombus", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Ventricular Tachycardia", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Post Procedural Myocardial Infarction", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 124}]}, {"term": "Incision Site Haematoma", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Incision Site Haemorrhage", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Vascular Pseudoaneurysm", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Wound Secretion", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Graft Haemorrhage", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Mental Status Change Postoperative", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Overdose", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Wound", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Haematoma", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 124}]}, {"term": "Haemorrhage", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Vascular Dissection", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Embolism", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Hypertensive Crisis", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Vessel Perforation", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Abdominal Pain Upper", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Gastrointestinal Angiodysplasia", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Gastrointestinal Haemorrhage", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Gastrointestinal Inflammation", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Dyspnea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Aspiration", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Bronchospasm", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Epitaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Pulmonary Oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Respiratory Failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Back Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Groin Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Neck Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Patellofemoral Pain Syndrome", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Haematuria", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Acute Kidney Injury", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Nephropathy", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Eye Pain", "organSystem": "Eye disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Ocular Hyperaemia", "organSystem": "Eye disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Vision Blurred", "organSystem": "Eye disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Dizziness", "organSystem": "Eye disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Neurological Decompensation", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Presyncope", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Agitation", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Delirium", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Contrast Media Allergy", "organSystem": "Immune system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Thrombosis in Device", "organSystem": "Product Issues", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 124}]}, {"term": "Testicular Haemorrhage", "organSystem": "Reproductive system and breast disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}, {"term": "Petechiae", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 209}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 202}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 124}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Randomization into the long tirofiban arm was initiated after 159 patients were already enrolled into either the short tirofiban or long eptifibatide arms."}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Kyle Brown", "organization": "Medicure", "email": "kbrown@medicure.com", "phone": "204-594-3411"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2018-02-01", "uploadDate": "2021-03-25T15:32", "filename": "Prot_000.pdf", "size": 768124}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2019-02-20", "uploadDate": "2021-03-25T15:33", "filename": "SAP_001.pdf", "size": 762518}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000009203", "term": "Myocardial Infarction"}, {"id": "D000054058", "term": "Acute Coronary Syndrome"}, {"id": "D000000789", "term": "Angina, Unstable"}, {"id": "D000007238", "term": "Infarction"}], "ancestors": [{"id": "D000007511", "term": "Ischemia"}, {"id": "D000010335", "term": "Pathologic Processes"}, {"id": "D000009336", "term": "Necrosis"}, {"id": "D000017202", "term": "Myocardial Ischemia"}, {"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000000787", "term": "Angina Pectoris"}, {"id": "D000002637", "term": "Chest Pain"}, {"id": "D000010146", "term": "Pain"}, {"id": "D000009461", "term": "Neurologic Manifestations"}], "browseLeaves": [{"id": "M27545", "name": "Acute Coronary Syndrome", "asFound": "Acute Coronary Syndrome", "relevance": "HIGH"}, {"id": "M16355", "name": "Syndrome", "relevance": "LOW"}, {"id": "M12155", "name": "Myocardial Infarction", "asFound": "Myocardial Infarction", "relevance": "HIGH"}, {"id": "M10282", "name": "Infarction", "asFound": "Infarction", "relevance": "HIGH"}, {"id": "M4117", "name": "Angina Pectoris", "relevance": "LOW"}, {"id": "M4119", "name": "Angina, Unstable", "asFound": "Unstable Angina", "relevance": "HIGH"}, {"id": "M10543", "name": "Ischemia", "relevance": "LOW"}, {"id": "M12284", "name": "Necrosis", "relevance": "LOW"}, {"id": "M6546", "name": "Coronary Artery Disease", "relevance": "LOW"}, {"id": "M19506", "name": "Myocardial Ischemia", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "M13066", "name": "Pain", "relevance": "LOW"}, {"id": "M5882", "name": "Chest Pain", "relevance": "LOW"}, {"id": "M12404", "name": "Neurologic Manifestations", "relevance": "LOW"}, {"id": "T170", "name": "Acute Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "BC10", "name": "Nervous System Diseases"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077466", "term": "Tirofiban"}, {"id": "D000077542", "term": "Eptifibatide"}], "ancestors": [{"id": "D000005343", "term": "Fibrinolytic Agents"}, {"id": "D000050299", "term": "Fibrin Modulating Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000010975", "term": "Platelet Aggregation Inhibitors"}], "browseLeaves": [{"id": "M9579", "name": "Heparin", "relevance": "LOW"}, {"id": "M46053", "name": "Calcium heparin", "relevance": "LOW"}, {"id": "M17544", "name": "Vitamin A", "relevance": "LOW"}, {"id": "M302395", "name": "Retinol palmitate", "relevance": "LOW"}, {"id": "M1807", "name": "Tirofiban", "asFound": "Pelvic Organ", "relevance": "HIGH"}, {"id": "M13865", "name": "Platelet Aggregation Inhibitors", "relevance": "LOW"}, {"id": "M1820", "name": "Eptifibatide", "asFound": "Graduate", "relevance": "HIGH"}, {"id": "M8473", "name": "Fibrinolytic Agents", "relevance": "LOW"}, {"id": "T468", "name": "Vitamin A", "relevance": "LOW"}, {"id": "T462", "name": "Retinol", "relevance": "LOW"}], "browseBranches": [{"abbrev": "FiAg", "name": "Fibrinolytic Agents"}, {"abbrev": "AnCoag", "name": "Anticoagulants"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Micro", "name": "Micronutrients"}, {"abbrev": "ANeo", "name": "Antineoplastic Agents"}, {"abbrev": "PlAggInh", "name": "Platelet Aggregation Inhibitors"}, {"abbrev": "Vi", "name": "Vitamins"}]}}, "hasResults": true}